• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h ventures has so far invested in 25 promising early stage biotech companies in the UK from the Human Health EIS fund as well as angel investments.

our full portfolio

Order

Default
A-Z Z-A Default

Status

All
Active Exited All

Therapeutics Area

All
All

Investment Type

All
Fund Investment Pre-Fund Investment All
Search
portfolio-image

Enedra Therapeutics Ltd

Developing the first personalised medicines that treat heterogeneous cancers, a formidable challenge in oncology

portfolio-image

Sansanima Ltd

Developing in vitro, cell-based assay technologies to replace animal testing.

portfolio-image

Atelerix Ltd

Hypothermic gel-based technology to preserve live cells, tissues and viruses at room temperature

portfolio-image

Revolver Therapeutics

An University of Bath spinout exploring new potential drug candidates for childhood glioma.

portfolio-image

Ascend Bio Ltd

A Company Pioneering Cell Therapy Cures

portfolio-image

Vesynta Ltd

Developing a clinical decision modelling software leveraging AI to maximise therapeutic potential and de-risk drug development.

portfolio-image

Clotprotect Therapeutics

Developing a first-in-class small molecule direct plasmin inhibitor for intravenous administration.

portfolio-image

Stratosvir

Developing viral immunotherapy for late-stage cancer by enabling intravenous delivery and facilitating multiple dosing.

portfolio-image

CamGene Therapeutics

A pre-seed company aiming to transform the treatment of hearing loss.

portfolio-image

CardiaTec Biosciences

Applying artificial intelligence on large-scale multiomic data to develop the next generation of cardiovascular disease drug targets

portfolio-image

Alevin Therapeutics

Developing a platform of novel small molecule RGD integrin inhibitors with superior drug-like qualities.

portfolio-image

Neurocentrx Pharma Ltd

Developing medicines to treat patients with neurological conditions.

portfolio-image

Xploro

Using artificial intelligence, augmented reality and games to reduce stress and anxiety and improve patient outcomes

portfolio-image

Neuroute

AI clinical development platform that enables transformative medicines

portfolio-image

BiVictriX

Leveraging frontline clinical experience for the development of next generation cancer therapies

portfolio-image

Sanome

An AI powered clinical decision support to improve patient outcomes

portfolio-image

Monument Therapeutics

Bringing Precision Medicine to Neuroscience Drug Development

portfolio-image

Stingray Bio

By targeting neglected but essential cancer kinases, the Company aims to generate next-generation oncology therapeutics for cancer patients.

portfolio-image

Kuano

De-risking and accelerating drug discovery by combining quantum and AI

portfolio-image

Spirea

Linking targeted cancer therapy to better patient outcomes

portfolio-image

Tay Therapeutics

Because skin matters

portfolio-image

Cortirio

Portable diagnosis of brain injuries

portfolio-image

Stemnovate

Drug Toxicity Testing

portfolio-image

Arecor

Developing ultra rapid and ultra concentrated insulin

portfolio-image

NeoPhore

Discovering novel medicines that uses the bodies immune system to fight cancer

portfolio-image

Opal Oncology

New therapeutics to treat brain cancer

portfolio-image

Sentinel Oncology

New medicines to treat cancer indications and rare diseases

portfolio-image

Talisman Therapeutics

Human stem cell drug discovery services

portfolio-image

Five Alarm Bio

Seeking to develop drugs to slow down the ageing process

portfolio-image

Oppilotech

New antibiotics to overcome drug resistance based on proprietary machine learning platform

portfolio-image

PhoreMost

New drug target identification platform

portfolio-image

Privitar

Data Privacy. Secondary, Series, Led by Warburg Pincus (~20X)

portfolio-image

Acacia Pharma

Novel medicine to support cancer therapy IPO MAR 2018 (EURONEXT: ACPH.BR (~9X))

portfolio-image

PharmEnable

Diverse database of synthesiable compounds used to find start points for new research programmes

portfolio-image

Qkine

Re-defining growth factor and cytokine quality to advance stem cell, organoid and regenerative medicine

portfolio-image

Heartfelt Technologies

Automatic, Non-Contact Home Heart Failure Monitoring For The Casually Compliant Patient

portfolio-image

Neurofenix

Developing medical devices for the upper limb rehabilitation of stroke patients

portfolio-image

Turbine

Turbine models how cancer works on the molecular level and tests millions of potential drugs on it with artificial intelligence

portfolio-image

Pencil Biosciences

Next generation gene editing technology

portfolio-image

AI VIVO

Intelligent Systems Pharmacology powered by Artificial Intelligence. Breakthrough information against COVID-19

portfolio-image

Small Pharma Limited

Use known actives in certain recreational drugs to treat mental health conditions

portfolio-image

ViaNautis

The 'bionic nanoparticle' company using Polynaut for Pharma services and live cell imaging

portfolio-image

Metrion Biosciences

Electrophysiology screening services to support client medicinal chemistry optimisation programmes

portfolio-image

DeepMatter

Digitizing pharmaceutical chemistry (AIM: DMTR.L)

portfolio-image

Oxford Drug Design

Machine learning platfrom used to find ligands for Aminoacyl tRNA Synthetases

portfolio-image

Exonate

Novel medicine as a drop to target disease of the eye

Sorry, no results found with this search

o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)